WO2009015515A1 - Composition pharmaceutique destinée à réguler la glycémie et la lipidémie, procédé de préparation et utilisation - Google Patents
Composition pharmaceutique destinée à réguler la glycémie et la lipidémie, procédé de préparation et utilisation Download PDFInfo
- Publication number
- WO2009015515A1 WO2009015515A1 PCT/CN2007/002307 CN2007002307W WO2009015515A1 WO 2009015515 A1 WO2009015515 A1 WO 2009015515A1 CN 2007002307 W CN2007002307 W CN 2007002307W WO 2009015515 A1 WO2009015515 A1 WO 2009015515A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- alcohol
- group
- extract
- turmeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a pharmaceutical composition for regulating blood sugar and blood lipids, and more particularly to a pharmaceutical composition prepared from a Chinese medicinal material or an extract thereof as an active ingredient, and a method for preparing the same, and a method for treating the same
- a pharmaceutical composition prepared from a Chinese medicinal material or an extract thereof as an active ingredient
- Diabetes is a common endocrine and metabolic disease, which is distributed throughout the world and is gradually increasing. The prevalence of diabetes in China has reached 15%. It already has the second largest population of diabetes in the world and is growing at a rate that doubles every 15 years.
- Type II diabetes is predominant in patients with diabetes. After insulin resistance (a condition in which normal doses of insulin produce a lower than normal biological effect) occurs, as long as the pancreas maintains a sufficiently high amount of insulin secretion to overcome insulin resistance, glucose tolerance will remain normal or only slightly impaired. Once p-cell function begins to fail, glucose tolerance will rapidly deteriorate and it will progress to diabetes. Insulin resistance is an important cause of type 2 diabetes. In the case of disorders of glucose metabolism, fat metabolism disorders are often accompanied. Therefore, improving insulin resistance, controlling disorders of glucose and fat metabolism, and preventing complications are the focus of diabetes treatment.
- One of the objects of the present invention is to provide a novel pharmaceutical composition for regulating blood sugar and blood lipids. Another object of the invention is to provide a process for the preparation of a pharmaceutical composition of the invention. A further object of the present invention is to provide a method of treating diabetes and its complications using the pharmaceutical composition of the present invention, or the use of the pharmaceutical composition of the present invention in the preparation of a medicament for treating diabetes and its complications.
- the inventors of the present application have found through long-term in-depth research that the principle of supplementing qi and nourishing yin and dissipating phlegm and blood stasis can provide an ability to regulate blood sugar, blood lipids, improve insulin resistance, and effectively prevent and treat diabetes.
- the above-mentioned purpose is achieved by drugs that cause complications.
- the present invention provides a pharmaceutical composition for regulating blood sugar and blood lipids, which comprises the following parts by weight of a Chinese medicinal material or an extract thereof: Ligustrum lucidum 5-17, Astragalus 3-12, Coptis 1-5, Litchi nucleus 1-5, 3 ⁇ 4 cloth 1-6 and turmeric 1-6.
- the present invention provides a pharmaceutical composition for regulating blood sugar and blood lipid, which is composed of the following parts by weight of a Chinese medicinal material or an extract thereof: Ligustrum lucidum 8-15, Astragalus 4-10, Coptis 2-3, Litchi nucleus 3-4, Khumbu 3-5 and turmeric 3-5.
- a Chinese medicinal material or an extract thereof Ligustrum lucidum 8-15, Astragalus 4-10, Coptis 2-3, Litchi nucleus 3-4, Khumbu 3-5 and turmeric 3-5.
- the present invention provides a pharmaceutical composition for regulating blood sugar and blood lipids, which is composed of the following parts by weight of a Chinese medicinal material or an extract thereof: Ligustrum lucidum 8 , Astragalus 4, Coptis 2, Litchi core 4, Laminaria 3 and Turmeric 3.
- the Chinese medicinal materials can be replaced with their solvent extracts, effective sites or active ingredients, respectively.
- the extract is an alcohol extract, a 7 extract or a volatile oil.
- the pharmaceutical composition according to the present invention may comprise an effective amount of Ligustrum alcohol extract, Corianol extract, Astragalus extract, Turmeric volatile oil, Turmeric water extract, Litchi nuclear water extract for treating or ameliorating diabetes and its complications. Things and kelp take things.
- composition according to the present invention may further comprise any excipient which is pharmaceutically acceptable, such as dextrin, preferably beta-dextrin.
- the components of the Chinese medicinal material can be replaced or increased or decreased according to the theory of traditional Chinese medicine, and the content of each component can also be varied.
- the kelp Can be used without, or replaced with kelp or seaweed; turmeric can be used, or replaced with turmeric or sputum.
- the present invention also provides a pharmaceutical composition for regulating blood sugar and blood lipids, which comprises the following Chinese herbal medicines or extracts thereof: Ligustrum lucidum 5-17, Astragalus 3-12, Coptis 1-5 and Litchi core 1 -5, and pharmaceutically acceptable excipients.
- the pharmaceutical composition according to the present invention which can be prepared together with any pharmaceutically acceptable excipient, is a dosage form commonly used in the field, such as tablets, granules or capsules. It is also possible to use a mixture of them directly, or to use a solvent extract of each component or mixture.
- the pharmaceutical composition of the present invention when using the thin layer chromatography method described in Appendix VIB of the Chinese Pharmacopoeia 2005 edition, oleanolic acid, berberine hydrochloride, baicalin and protocatechuic acid are used as reference materials respectively. Upon detection, the pharmaceutical composition exhibits spots of the same color at corresponding locations of the control.
- the specific identification is as follows.
- the above test solution solution 5 ⁇ 1, reference solution 10 ⁇ 1, respectively, on the same silica gel G thin layer plate with carboxymethyl cellulose sodium as a binder, with petroleum ether - Acetone-methanol (8:2:0.3) was used as a developing solvent, unrolled, taken out, air-dried, and sprayed with 10% sulfuric acid in ethanol at 80. C is heated until the spots are clear.
- spots of the same color are displayed at positions corresponding to the chromatogram of the reference substance.
- the thin layer chromatography (Appendix IB) test take the above test solution 2 ⁇ 1, the reference solution 2 ⁇ 1, respectively, on the same silica gel G thin layer plate with sodium carboxymethyl cellulose as the binder, with benzene-acetic acid Ethyl-isopropyl alcohol-methanol-water (6: 3: 1.5: 1.5: 0.3)
- the ammonia vapor is saturated in the unrolling cylinder, unrolled, taken out, dried, and placed under ultraviolet light (365 nm) for inspection.
- fluorescent spots of the same color are displayed at positions corresponding to the chromatogram of the reference substance.
- the pharmaceutical composition according to the present invention when tested by high performance liquid chromatography as described in Appendix VI D of the Chinese Pharmacopoeia 2005 edition, and using oleanolic acid and ursolic acid as a control substance,
- the content of oleic acid and ursolic acid is not less than 4.0 mg And 1.0 mgo were determined as follows.
- the octadecylsilane-bonded silica gel was used as a filler; decyl alcohol-0.05% phosphoric acid water (90:10) was used as a mobile phase; the detection wavelength was 215 nm.
- the number of theoretical plates should be no less than 3,000 in terms of oleanolic acid. Accurately weigh the appropriate amount of oleanolic acid and ursolic acid reference substance, add acetonitrile to make a solution containing 0.20mg of citric acid and 0.15mg of ursolic acid per lml, that is, the reference solution is obtained.
- the invention provides a method of preparing a pharmaceutical composition of the invention, the method comprising the steps of:
- the scorpion is heated and refluxed with ethanol, extracted several times, combined with the alcohol extract, the alcohol is recovered, and the extract is dried for use;
- the turmeric is extracted by steam distillation, and the volatile oil is collected, and the aqueous solution and the dregs are used; the obtained volatile oil is encapsulated with cyclodextrin and water, stirred, refrigerated, filtered, and the obtained inclusion is dried at a low temperature, pulverized, and used;
- the litchi nucleus and kelp are fried several times with water, combined with decoction, filtered, and the filtrate is combined with the above aqueous turmeric solution, concentrated, added with alcohol, refrigerated, filtered, and the decoction of the alcohol solution is used;
- Coptis, Astragalus and the above turmeric residue are heated and refluxed with alcohol, extracted several times, combined with the alcohol extract and combined with the above-mentioned decoction and alcohol precipitation liquid, the alcohol is recovered, dried and combined with the above-mentioned Ligustrum alcohol extract, turmeric cyclodextrin
- the fine powder of the knot is mixed, and if necessary, it is mixed with a pharmaceutically acceptable auxiliary material to prepare a desired dosage form.
- the optimum conditions for the extraction of volatile oil from turmeric are: 10 mesh turmeric plus 10 times water.
- the volatile oil is extracted by steam distillation, and the volatile oil extraction time is 8 hours.
- the volatile oil was mixed with 6 times the amount of betacyclodextrin and 60 times of water, stirred at 70 ° C for 1 hour, refrigerated overnight, filtered, and the inclusions were dried at a low temperature (40 ° C), pulverized into fine powder. , spare.
- the blood glucose of the high-dose group was significantly reduced (compared with the model group ⁇ 0 ⁇ 001), and the hypoglycemic rate reached 31.23%.
- the pharmaceutical composition of the present invention has a hypoglycemic and lipid-lowering effect on type II diabetic rats.
- a real face study of rats with fast-onset diabetes showed that rats developed a rat model of fast-onset diabetes (type I diabetes) after STZ injection.
- the blood glucose of each dose group of the present invention was significantly reduced, compared with the model group ( ⁇ ⁇ 0.05).
- the percentage of glycated hemoglobin and glycated hemoglobin decreased significantly ( ⁇ 0.05 ⁇ 0 ⁇ 01) and glucagon decreased ( ⁇ 0.05).
- the insulin level increased and the food intake decreased to varying degrees, but it was not statistically significant. It is indicated that the pharmaceutical composition of the present invention has hypoglycemic effect on fast-rising diabetic rats.
- the present invention also provides a method of treating diabetes using the pharmaceutical composition of the present invention. And methods of its complications, or the use of a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of diabetes and its complications. detailed description
- the Chinese medicinal materials used in the following examples were purchased from the Hebei Anguo Chinese Herbal Medicine Trading Market. The relevant experts have been appraised and tested, and all of them comply with the relevant provisions of the 2005 edition of the Chinese Pharmacopoeia.
- Dextrin was purchased from Langfang Starch Factory in Hebei province; batch number: 200308202; ⁇ (1998) No. 090127; Betacyclodextrin was purchased from Nankai University Fine Chemical Experiment Factory; Batch No.: 20000804. Other reagents are commercially available.
- Example 1 Preparation of pharmaceutical composition (granule) of the present invention
- Ligustrum lucidum is heated and refluxed with 6 times 75% ethanol, extracted three times for 2 hours each time, combined with ethanol extract, and the drug solution is reserved; berberine, astragalus plus 6 times 50% ethanol is heated and refluxed, and extracted three times each time.
- the scorpion is extracted three times with 6 times 75% ethanol and refluxed three times for 2 hours each time.
- the ethanol extract is combined, the ethanol is recovered, dried, and used; the turmeric is crushed and added with 10 times the amount of water, and steam distilled for 8 hours.
- the volatile oil is collected, the aqueous solution is reserved, and the dregs are dried for use; the volatile oil is coated with 8 times the amount of cyclodextrin and 80 times of water, 50.
- the scorpion is extracted three times with 6 times 75% ethanol and refluxed three times for 2 hours each time.
- the ethanol extract is combined, the ethanol is recovered, dried, and used; the turmeric is crushed and added with 10 times the amount of water, and steam distilled for 8 hours.
- the volatile oil is collected, the aqueous solution is reserved, and the dregs are dried for use; the volatile oil is coated with 8 times the amount of cyclodextrin and 80 times of water, stirred at 50 ° C for 1 hour, refrigerated overnight, filtered, and the inclusions are dried at low temperature ( 40'C), pulverized into fine powder, spare; lychee core, kelp plus 10 times the amount of water, decocted three times, each time 0.5 hours, combined with decoction, filtered, the filtrate was combined with the above aqueous turmeric solution, the combined solution was concentrated to relative Density 1.10-1.15 (50 ° C measured), add ethanol to make the alcohol content up to 60%, refrigerate overnight, filtered, and the filtrate is ready for use; berberine, astragalus and turmeric dregs are extracted three times with 6 times 50% ethanol and refluxed three times.
- the scorpion is extracted three times with 6 times 75% ethanol and refluxed three times for 2 hours each time.
- the ethanol extract is combined, the ethanol is recovered, dried, and used; the turmeric is crushed and added with 10 times the amount of water, and steam distilled for 8 hours.
- the volatile oil is collected, the aqueous solution is reserved, and the dregs are dried for use; the volatile oil is coated with 8 times the amount of cyclodextrin and 80 times of water, 50.
- Example 5 Experimental study of the pharmaceutical composition of the present invention in type II diabetic rats 1. Experimental materials
- Main nutrients crude protein ⁇ 18%, crude fiber ⁇ 5%, coarse ash ⁇ 8%, calcium 0.8-1.8%, monument 0.6-1.2%, lysine ⁇ 1.35%, salt 0.5%, water ⁇ 10% , a variety of vitamins and trace elements.
- the high-fat and high-sugar feed is processed by the Experimental Animal Center of the Chinese Academy of Military Medical Sciences.
- the pharmaceutical composition of the present invention It was used to extract clear bone, 3.37 g of crude drug/ g bone, batch number: 050401, and was prepared according to the method shown in Example 4.
- Dioxin hydrochloride tablets 0.25g / tablet, batch number: 041226, produced by Beijing Liling Hengtai Pharmaceutical Co., Ltd., Chinese medicine standard H11021560.
- Jinqi Jiangtang Tablets 0.42 g / piece, batch number: 0503746, produced by Tianjin Zhongxin Pharmaceutical Group Co., Ltd. Longshunyi Pharmaceutical Factory, National Medicine Zhunzi Z10920027.
- the experiment was set up in the normal diet group and the high-fat and high-sugar diet group. After one month of feeding on the high-fat and high-sugar diet, the rats were induced to insulin resistance, and then induced by intraperitoneal injection of 25 mg/kg streptozotocin (STZ) twice. Glucose, fasting blood glucose was measured 72 hours later, and rats were successfully modeled with more than 16.7 mmol/l.
- Grouping (1) blank control group (common feed + 0.1M citrate buffer intraperitoneal injection); the following groups are high-fat and high-sugar feed plus STZ>0.1M citrate buffer intraperitoneal injection, (2) model group (3) The positive drug diterpene bismuth group 0.2g/kg; (4) The positive drug jinqi hypoglycemic tablet group 2g/kg; (5) The pharmaceutical composition of the invention high dose group 8g crude drug/kg (6) In the pharmaceutical composition of the invention, the dosage group of 4 g of crude drug/kg; (7) The pharmaceutical composition of the present invention is a small dose group of 2 g of crude drug/kg.
- each group was intragastrically administered with a dose and continued to feed with high-fat and high-sugar diet for one month.
- Blood weight and food intake are measured weekly, and blood glucose is measured every other week.
- the active blood of the abdomen after anesthesia was measured for blood glucose, blood lipids, insulin, tumor necrosis factor, interleukin-6 and other indicators.
- the pancreas and liver were taken for pathological sectioning, and the heart, liver, and kidney were weighed, and the organ index was calculated: organ weight/body weight xlOO (g/100g). Results were statistically processed (t-test). 3.
- Rats in the high-fat and high-sugar diet group were tested for fasting blood glucose after 72 hours of intraperitoneal injection of STZ.
- the blood glucose levels were significantly higher in the pre-medication group compared with the control group (P ⁇ 0.001), and the average blood glucose level was around 25-26 mmol/l.
- Each group was administered by continuous intragastric administration for two months.
- the high-dose group of the pharmaceutical composition of the present invention can reduce the blood glucose of rats ( ⁇ 0 ⁇ 05 ⁇ 0.01) at 2, 4, and 6 weeks, and the effect is obvious at 8 weeks. ( ⁇ 0.001).
- the rate of glucose reduction reached 31.23%.
- composition of the present invention for type II diabetes The effect of food intake in rats ⁇ s) group 5 weeks after drug 5 weeks after drug 6 weeks after drug 8 weeks after drug control group 3.5 3.59 ⁇ 0. 35 5.31 ⁇ 1.34 4 ⁇ '40 ⁇ 0.07 4.78 ⁇ 0.11 model group 11 18.30 ⁇ 0.94** 19.68 ⁇ 0.61** 21.56 ⁇ 3.21* 20.48 ⁇ 4.22* Metformin group 12 13 ⁇ 38 ⁇ 1 .79 15.31 ⁇ 1.59 16.96 ⁇ 2.60 15.59 ⁇ 2.65 ⁇ PHI film group 8 14.12 ⁇ 0.
- the experimental results showed that rats developed hyperinsulinemia with high blood sugar and cholesterol at one month on a high-fat and high-sugar diet, and successfully induced insulin resistance.
- a rat model of type II diabetes was induced by intraperitoneal injection of STZ. After continuous intragastric administration for two months, the blood glucose of the high-dose group was significantly reduced, and the hypoglycemic rate reached 31.23%. The blood lipids in the large and middle dose groups were significantly reduced.
- the pharmaceutical composition of the present invention has a hypoglycemic and lipid-lowering effect on type II diabetic rats.
- Example 6 The pharmaceutical composition of the present invention is in the form of rapid diabetes mellitus, type 2 diabetes mellitus)
- Wistar species II male rats Wistar species II male rats, weighing 180-200g, by Chinese medical science Provided by the Institute of Laboratory Animals, license number: SCXK Jing 2000-0006. Raised at the Experimental Animal Center of Xiyuan Hospital of China Academy of Chinese Medical Sciences, secondary animal breeding facility, certificate number: ⁇ ( ⁇ ) SYXK No. 2003-0008. Room temperature: 22-25'C, relative humidity: 45-60%.
- the pharmaceutical composition of the present invention The extract was prepared by the experiment, 3.37 g of crude drug/ g , lot number: 050401, and prepared according to the method shown in Example 4.
- Metformin Hydrochloride Tablets 0.25g/tablet, batch number: 041226, produced by Beijing Liling Hengtai Pharmaceutical Co., Ltd., National Pharmaceutical Standard H11021560.
- Jinqi Jiangtang Tablets 0.42 g / piece, batch number: 0503746, produced by Tianjin Zhongxin Pharmaceutical Group Co., Ltd. Longshunyi Pharmaceutical Factory, National Medicine Zhunzi Z10920027.
- Citric acid and sodium citrate produced by Beijing Chemical Plant, batch number: 960904.
- Blood glucose test strip produced by Roche, Germany, Roche Diagnostics (Shanghai) Co., Ltd., batch number: 22898731.
- Insulin Discharge Kit Beijing Furui Bioengineering Co., Ltd., batch number: 200601.
- Glucagon radioimmunoassay kit Beijing Atomic High-Tech Nuclear Technology Application Co., Ltd., batch number: 200601.
- Glycated hemoglobin produced by Roche, Germany, batch number: 200512.
- Wistar species II male rats were used in the experiment and weighed 180-200 g. All the groups were injected with streptozotocin (STZ) in the tail vein (90 mg/kg, 0.1 M. The citric acid buffer was prepared. The fasting blood glucose was measured 72 hours later, and the rats were successfully modeled with more than 16.7 mmol/l.
- STZ streptozotocin
- the drug composition of the present invention is a dose group of 4 g crude drug/kg; (7) The pharmaceutical composition of the present invention is a small dose group of 2 g crude drug/kg. All groups except the blank control group and the model group were administered by intragastric administration. Body weight is measured weekly, and blood glucose is measured every other week.
- the abdominal aorta was taken from whole blood (25 ulEDTA + 1 ml whole blood anticoagulation) to measure glycated hemoglobin, separated serum to determine insulin, and separated plasma (25 ulEDTA + 1 ml whole blood anticoagulation) to measure glucagon and other indicators.
- the pancreas was taken for pathological section (HE staining and aldehyde complex red staining). The results were statistically processed (t face).
- HBAlc glycated hemoglobin
- Halc% glycosylated hemoglobin ratio
- the drug composition of the present invention was administered by continuous intragastric administration for two months. Compared with the model group, the insulin level was increased, but it was not statistically significant. Glucagon was decreased in the high-dose group compared with the model group (P ⁇ 0.05). The results are shown in Table 25. Table 25. Effect of the pharmaceutical composition of the present invention on blood insulin and glucagon in fast-acting diabetic rats (:?)
- Control group 13 14.92 ⁇ 7.18 219.72 ⁇ 42.88 Model group 13 4,72 ⁇ 1.79 *** 445.63 ⁇ 134.52 *** Metformin group 0.2 12 5.51 ⁇ 2.21 337.35 ⁇ 70.83 # ⁇ 2 11 4.38 ⁇ 1.81 349.39 ⁇ 96.65
- the high dose group of the present invention 8 11 4.88 ⁇ 1.23 350.35 ⁇ 73.99 #
- the medium dose group of the invention 4 12 5.34 ⁇ 1.49 380.11 ⁇ 130.68
- the low dose group of the invention 2 10 4.85 ⁇ 0.85 406.54 ⁇ 140.05
- the low-dose group of the invention 197 ⁇ 69 ⁇ 15.85 200. .00 ⁇ 34.05 201. ,20 ⁇ 41.
- Rats were injected with STZ to form a rat model of immediate diabetes (type I diabetes). After continuous administration for two months, the blood glucose of each dose group of the pharmaceutical composition of the present invention was significantly reduced. Compared with the model group, the percentage of glycated hemoglobin and glycated hemoglobin decreased significantly, and glucagon decreased. The insulin level increased and the food intake decreased to varying degrees, but it was not statistically significant.
- the pharmaceutical composition of the present invention has a hypoglycemic effect on fast-rising diabetic rats.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/002307 WO2009015515A1 (fr) | 2007-07-31 | 2007-07-31 | Composition pharmaceutique destinée à réguler la glycémie et la lipidémie, procédé de préparation et utilisation |
AU2007357043A AU2007357043B2 (en) | 2007-07-31 | 2007-07-31 | Pharmaceutical composition for regulating blood sugar and fat, preparation and use thereof |
CN2007800146228A CN101472600B (zh) | 2007-07-31 | 2007-07-31 | 一种调节血糖、血脂的药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/002307 WO2009015515A1 (fr) | 2007-07-31 | 2007-07-31 | Composition pharmaceutique destinée à réguler la glycémie et la lipidémie, procédé de préparation et utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009015515A1 true WO2009015515A1 (fr) | 2009-02-05 |
Family
ID=40303862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/002307 WO2009015515A1 (fr) | 2007-07-31 | 2007-07-31 | Composition pharmaceutique destinée à réguler la glycémie et la lipidémie, procédé de préparation et utilisation |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101472600B (zh) |
AU (1) | AU2007357043B2 (zh) |
WO (1) | WO2009015515A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772540A (zh) * | 2011-05-11 | 2012-11-14 | 河北以岭医药研究院有限公司 | 一种治疗代谢综合征的药物 |
CN103623110A (zh) * | 2013-12-13 | 2014-03-12 | 广州大正新材料科技有限公司 | 一种减肥粉及其制备方法 |
CN109100463A (zh) * | 2018-10-25 | 2018-12-28 | 吕梁学院 | 一种北芪菇中黄芪苷的提取纯化与检验方法 |
CN113030365A (zh) * | 2021-03-10 | 2021-06-25 | 贵州百灵企业集团制药股份有限公司 | 一种主治实热火毒,三焦热盛之证的中药制剂及检测方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352974A (zh) * | 2014-11-11 | 2015-02-18 | 成都华熹科技有限公司 | 一种含朱砂莲的治疗糖尿病的中药组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386539A (zh) * | 2002-06-04 | 2002-12-25 | 潘强恩 | 治疗糖尿病的配方 |
CN1456328A (zh) * | 2003-03-24 | 2003-11-19 | 孙百忍 | 一种五梅降糖脂胶囊 |
CN1895547A (zh) * | 2006-06-16 | 2007-01-17 | 魏四清 | 一种治疗糖尿病的药物及制备方法 |
CN1895399A (zh) * | 2006-06-14 | 2007-01-17 | 高健生 | 一种治疗早期糖尿病视网膜病变的中药制剂 |
CN101002888A (zh) * | 2006-01-16 | 2007-07-25 | 陈维森 | 复方糖尿康 |
-
2007
- 2007-07-31 CN CN2007800146228A patent/CN101472600B/zh active Active
- 2007-07-31 WO PCT/CN2007/002307 patent/WO2009015515A1/zh active Application Filing
- 2007-07-31 AU AU2007357043A patent/AU2007357043B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386539A (zh) * | 2002-06-04 | 2002-12-25 | 潘强恩 | 治疗糖尿病的配方 |
CN1456328A (zh) * | 2003-03-24 | 2003-11-19 | 孙百忍 | 一种五梅降糖脂胶囊 |
CN101002888A (zh) * | 2006-01-16 | 2007-07-25 | 陈维森 | 复方糖尿康 |
CN1895399A (zh) * | 2006-06-14 | 2007-01-17 | 高健生 | 一种治疗早期糖尿病视网膜病变的中药制剂 |
CN1895547A (zh) * | 2006-06-16 | 2007-01-17 | 魏四清 | 一种治疗糖尿病的药物及制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772540A (zh) * | 2011-05-11 | 2012-11-14 | 河北以岭医药研究院有限公司 | 一种治疗代谢综合征的药物 |
CN103623110A (zh) * | 2013-12-13 | 2014-03-12 | 广州大正新材料科技有限公司 | 一种减肥粉及其制备方法 |
CN109100463A (zh) * | 2018-10-25 | 2018-12-28 | 吕梁学院 | 一种北芪菇中黄芪苷的提取纯化与检验方法 |
CN109100463B (zh) * | 2018-10-25 | 2020-09-25 | 吕梁学院 | 一种北芪菇中黄芪苷的提取纯化与检验方法 |
CN113030365A (zh) * | 2021-03-10 | 2021-06-25 | 贵州百灵企业集团制药股份有限公司 | 一种主治实热火毒,三焦热盛之证的中药制剂及检测方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2007357043A1 (en) | 2009-02-05 |
CN101472600B (zh) | 2011-12-07 |
AU2007357043B2 (en) | 2010-11-11 |
CN101472600A (zh) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001001996A1 (en) | Compositions and methods for treating or preventing osteoporosis | |
CN113018405B (zh) | 一种治疗脑卒中后抑郁症的中药组合物及制备方法 | |
WO2009015515A1 (fr) | Composition pharmaceutique destinée à réguler la glycémie et la lipidémie, procédé de préparation et utilisation | |
CN1275639C (zh) | 一种治疗妇科习惯性流产和先兆性流产疾病的药物及其制备方法 | |
CN101057925B (zh) | 接骨七厘胶囊制备工艺 | |
CN1985927B (zh) | 一种主要用于肝脏疾病的药物组合物 | |
WO2013155995A1 (zh) | 一种调节血脂的红曲葛根药物组合及其制备方法 | |
RU2409381C1 (ru) | Фармацевтическая композиция для регулирования сахара и жира в крови, ее получение и применение | |
CN113713039A (zh) | 一种治疗膜性肾病的中药组合物及其应用 | |
CN1985891B (zh) | 一种具有保肝作用的中药有效部位复方制剂及其制备方法 | |
CN102920964B (zh) | 一种治疗咳嗽的中药制剂 | |
CN110585262B (zh) | 一种治疗和/或预防肝胆疾病的中药组分组合物及其应用 | |
CN115531463A (zh) | 一种治疗高脂血症的中药 | |
CN111253459B (zh) | 一种三七皂苷炮制品及其制备方法和应用 | |
CN1823943A (zh) | 一种中药脑得生浓缩丸的制备工艺 | |
CN101147767B (zh) | 一种治疗痤疮的药物组合物胶囊剂的制备方法 | |
CN107997170B (zh) | 一种具有降血脂功能的组合物及其制备方法 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN109303800A (zh) | 一种降脂护肝组合物及其制备方法和应用 | |
CN115770266B (zh) | 一种用于治疗绝经后骨质疏松的药物组合物 | |
CN106466396B (zh) | 一种妇科调经缓释滴丸及其制备方法 | |
WO2014086255A1 (zh) | 山药多糖和山药蛋白质的组合物的用途 | |
CN115779039B (zh) | 一种用于治疗绝经后骨质疏松的药物组合物 | |
CN100579567C (zh) | 一种中药制剂在制备预防冠心病药物中的用途 | |
CN101919984A (zh) | 一种治疗甲亢的药物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780014622.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07785221 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007357043 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009119719 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007357043 Country of ref document: AU Date of ref document: 20070731 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07785221 Country of ref document: EP Kind code of ref document: A1 |